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Vertical sleeve gastrectomy (VSG) has gained interest as a low morbidity bariatric surgery, which
is effective in producing weight loss and causing type 2 diabetes resolution. However, the efficacy
of VSG to prevent the onset of type 2 diabetes has not been previously investigated. VSG or sham
surgery was performed on 2-month-old prediabetic male University of California Davis-type 2
diabetesmellitus rats. Sham-operated animals were either sham-operated ad libitum fed (S-AL) or
wereweight-matched toVSG-operatedanimals (S-WM).Diabetesonsetwasdeterminedbyweekly
nonfasting blood glucosemeasurements. Animals underwent oral glucose tolerance tests at 1 and
4 months after surgery and indirect calorimetry at 1.5 months after surgery. VSG surgery signifi-
cantly delayed diabetes onset comparedwith both S-AL and S-WManimals. VSG-operated animals
ate 23% less and weighed 20% less than S-AL. Energy expenditure did not differ between VSG-
operatedanimals andcontrols. Results fromtheoralglucose tolerance testsdemonstrate improved
glucose tolerance and islet function in VSG-operated animals compared with S-AL and S-WM.
Nutrient-stimulatedglucagon-likepeptide (GLP)-1, GLP-2, andpeptideYYexcursionsweregreater
in VSG-operated animals. VSG surgery resulted in decreased fasting plasma insulin, ghrelin and
lipid concentrations, andmarkedlyhigher fastingplasmaadiponectinandbileacid concentrations,
independentof bodyweight. Increases of circulatingbile acid concentrationsweredue to selective
increases of taurine-conjugated bile acids. Thus, VSG delays type 2 diabetes onset in the University
of California Davis-type 2 diabetes mellitus rat, independent of body weight. This is potentially
mediated by increases of circulating bile acids, adiponectin, and nutrient-stimulated GLP-1 secre-
tion and decreased circulating ghrelin concentrations. (Endocrinology 153: 3620–3632, 2012)
Bariatric surgery is currently the most effective long-term treatment for obesity and often results in reso-
lution of type 2 diabetes (1) andmay also prevent or delay
the onset of diabetes (2, 3). However, the mechanisms by
which thisoccurs remainundefined. Identificationof these
mechanisms may provide new therapeutic targets for the
treatment and prevention of type 2 diabetes. Vertical
sleeve gastrectomy (VSG)has gained interest as a lowmor-
biditybariatric surgery that is highly effective inproducing
weight loss and improving glucose homeostasis. VSG in-
volves removal of the greater curvature of the stomachand
thus has been considered to be primarily a restrictive sur-
gery. However, retrospective studies have revealed that
VSG reverses diabetes in 80–84% of patients with type 2
diabetes (4–6) with improvements of circulating insulin
and glucose concentrations observed as early as 3 d post-
operatively and before any significant weight loss (7). In-
terestingly, VSG has been shown to produce diabetes re-
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mission and improved glucose homeostasis to a similar
degree asRoux enYgastric bypass (RYGB) in both rodent
andhumanclinical studies (4, 8). Furthermore, recent clin-
ical studies in humans have shown that, similar to RYGB,
metabolic improvements after VSG may be related to in-
creases of nutrient-stimulated glucagon-like peptide
(GLP)-1 and peptide YY (PYY) secretion (9). In addition,
VSG results in marked decreases of circulating ghrelin
concentrations, which have been postulated to contribute
to greater early excess body weight loss (10).
In addition to the well-described effects of ghrelin to
increase appetite, ghrelin also influences fat mass, growth
hormone secretion, and glucose homeostasis. Ghrelin is
primarily produced in the gastric mucosa and its receptor
(GH secretagogue receptor-1a) is expressed on hypotha-
lamic cells, pituitary, liver, adipocytes, and pancreas (11).
Furthermore, GH secretagogue receptor-1a and ghrelin
are both expressed in pancreatic -, -, and -cells (12–
14). Recent studies suggest that excess ghrelin production
could contribute to the development of type 2 diabetes,
because ghrelin has been shown to impair glucose-stimu-
lated insulin secretion and promote insulin resistance
(15–17).
GLP-1 and PYY are secreted by L cells, located primar-
ily in the distal small intestine, in response to direct stim-
ulation by nutrients and by vagal stimulation (18, 19).
PYYacts todecrease food intakeand thusmaintainweight
loss (20). GLP-1 acts to decrease food intake, increase
glucose-stimulated insulin secretion and improve insulin
sensitivity, and may preserve islet integrity (18).
In the present study, we used the University of Califor-
nia Davis-type 2 diabetes mellitus (UCD-T2DM) rat
model of type 2 diabetes to investigate the effects of VSG
on the onset of diabetes. The UCD-T2DM rat model de-
velops adult-onset polygenic obesity, insulin resistance,
and hyperglycemia, without a defect in leptin signaling,
making this model ideal for investigating the efficacy of
VSG to delay type 2 diabetes onset (21). Previous rodent
studies of VSG surgery have used models of obesity such
as Zucker rats (22) and high-fat-fed Long-Evans rats (8).
To our knowledge, this is the first study of the effects of
VSG in an animal model of type 2 diabetes. Here, we
report that VSG significantly delayed diabetes onset and
was accompanied by significant improvements of insulin
secretion and glucose and lipidmetabolism. Furthermore,
VSG-operated animals exhibited marked increases of nu-
trient-stimulated GLP-1, GLP-2, and PYY secretion, de-
creased fasting plasma ghrelin concentrations, and in-
creased fasting plasma adiponectin and bile acid
concentrations, which are likely contributors to the delay
in diabetes onset.
Materials and Methods
Diets and animals
Male UCD-T2DM rats were individually housed in hanging
wire cages in the animal facility in the Department of Nutrition
at the University of California Davis and maintained on a 14-h
light, 10-h dark cycle. At 2 months of age rats underwent sham
or VSG surgery. Sham-operated animals were then divided into
sham-operated ad libitum-fed (S-AL) or sham-operated weight-
matched (S-WM) groups. Animals were followed until at least 8
months of age to determine the time to diabetes onset. Baseline
body weights, measured on the day of surgery, were 385  10,
385 6, and 385 7 g in S-AL (n 14), S-WM (n 16), and
VSG-operated animals (n  13), respectively. All animals re-
ceived ground chow (no. 5012; Ralston Purina, Belmont, CA).
Food intake and body weight were measured three times a week
in S-AL andVSG-operated animals, and S-WManimals received
daily rations of food to match their body weights with the VSG-
operated animals. Nonfasting blood glucose was measured
weeklywith a glucometer (One-TouchUltra; LifeScan,Milpitas,
CA) at 1400–1600 h. Diabetes onset was defined as a nonfasted
blood glucose value above 11.1 mmol/liter (200 mg/dl) for two
consecutive weeks. Indirect calorimetry was performed at 1.5
months after surgery using an Integra ME system (AccuScan,
Columbus, OH). The experimental protocols were approved by
the University of CaliforniaDavis Institutional Animal Care and
Use Committee.
Bariatric procedures, including VSG surgery, can result in
malabsorption of certain vitamins and minerals, including vita-
min B12, often necessitating supplementation (23). In the rat,
vitamin B12 deficiency can result from removal of the glandular
portion of the stomach at 1–3 months after surgery, leading to
the subsequent development of anemia.The glandular portionof
the stomach is responsible for producing intrinsic factor, which
is necessary for vitamin B12 absorption (24). To control for this,
hematocrit was monitored, and when mild anemia was noted,
vitamin B12 supplementationwas initiated in VSG-operated an-
imals. At 5 months after surgery, mild anemia was first noted in
the VSG-operated animals (hematocrit, 34  2%; rat reference
range, 35–45%) (25). VSG-operated animals received 50 g of
cyanocobalamin sc onceweekly thereafter (25). After onemonth
of treatment, hematocrit values in VSG-operated animals were
normalized to 40  2% and remained stable thereafter.
VSG surgery
Rats were placed on a liquid diet (Boost, Novartis, Minne-
apolis, MN) 4 d before surgery and for 14 d after surgery and
received enrofloxacin (20 mg/kg, sc once daily) and meloxicam
(2mg/kg sc once daily). Anesthesia was induced andmaintained
with isoflurane (2–5%). A midline abdominal incision was
made, and connective tissue attachments to the liver and spleen
were transected to allow isolation of the stomach outside the
abdominal cavity. The stomach was packed-off with gauze
sponges and 4–0 polydioxanone (PDS) suture (Ethicon, Corne-
lia, GA) was used to create a line of sutures encompassing both
gastric walls just below the intended incision. Hemostats were
placed just above the intended incision, and approximately 70%
of the stomach (including the entire fundus) was removed by
cutting along the greater curvature between the suture line and
the hemostats to create a tubular remnant connecting the esoph-
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agus and pylorus. A second line of sutures was placed using 6–0
PDS (Ethicon) to reinforce apposition of the gastricmucosa. The
gastric remnantwas lavaged and placed back into the abdominal
cavity. The abdominal cavity was closed in two layers using 4–0
PDS (Ethicon).
Sham-operated animals were treated in similar manner as the
VSG group. Sham surgeries were performed by making a lapa-
rotomy incision and isolating the stomach outside of the abdom-
inal cavity. A simple continuous pattern of suture was placed
through one layer of the greater curvature of the stomach in the
same locationas theVSG-operatedanimalsusing6–0PDS (Ethi-
con) along both gastric walls. The stomach was lavaged and
returned to the abdominal cavity.
Oral glucose tolerance tests (OGTT)
At 1 and 4 months after surgery, OGTT were performed.
Animals were fasted overnight (12 h) and then received a 50%
dextrose solution (1 g/kgbodyweight) byoral gavage. Bloodwas
collected from the tail for measurement of glucose and insulin
concentrations. A second aliquot of blood was placed in tubes
containing EDTA, aprotinin, and a dipeptidyl peptidase-IV in-
hibitor and analyzed for GLP-1 and PYY. Serum glucose was
measured using an enzymatic colorimetric assay for glucose
(ThermoDMA, Louisville, CO). Serum insulinwasmeasured by
ELISA (Millipore, St. Charles,MO). Total GLP-1wasmeasured
by sandwich electrochemiluminescence immunoassay (Meso
ScaleDiscovery,Gaithersburg,MA). PlasmaPYYwasmeasured
by RIA (Millipore).
Monthly fasted hormone and metabolite profiles
Baseline and monthly blood samples were collected after an
overnight (12 h) fast from the tail. Plasma was assayed for glu-
cose, insulin, triglycerides (TG), cholesterol, leptin, adiponectin,
and ghrelin. Plasma glucose, cholesterol, and TGweremeasured
using enzymatic colorimetric assays (Thermo DMA; L-type TG
H kit, Wako Chemicals USA, Inc., Richmond, VA). Leptin and
adiponectinweremeasuredwith rodent/rat-specificRIA (rat lep-
tin, mouse adiponectin; Millipore). Insulin was measured by
ELISA (Millipore). Ghrelin was measured by sandwich electro-
chemiluminescence immunoassay (Meso Scale Discovery).
Monthly fasting plasma bile acid profiles
Monthly bile acid profiles were analyzed as previously de-
scribed (26, 27). An internal standard mixture of D4-cholate,
D4--muricholate, D4-a-muricholate, D4-chenodeoxycholate,
D4-deoxycholate, D4-hyodeoxycholate, D4-ursodeoxycholate,
and D4-lithocholate, and their tauroconjugated and glycocon-
jugated counterparts, was prepared in acetonitrile. Eluted bile
salts were detected by negative ion, electrospray mass spectrom-
etry on a linear trap linear ion trap mass spectrometer (Thermo-
Finnigan, San Jose, CA) using a data-dependent stage of detec-
tion triggering a qualitative 0 m/z neutral loss scan at 27%
normalized collision energy. Peak areas from initial scans of in-
dividual bile salts at 514.3, 498.3, 464.3, 447.3, 411.3, 407.3,
395.3, 393.3, and 391.3m/z were integrated, and response fac-
tors were defined by peak area ratios of analytes to that of in-
ternal, deuterated standards. The response factors were read
against those obtained fromstandard curves in surrogatematrix,
and molar levels of serum or plasma levels were interpolated
from standard curves. Response factors for all samples were
comprised of peak area ratios of nonlabeled salts normalized to
the stable-labeled counterparts. Concentrations were interpo-
lated by linear regression from curves of known standards.
Cell culture
3T3-L1 cells were maintained in high glucose (25 mM)
DMEM supplemented with 10% newborn calf serum and pen-
icillin-streptomycin.When confluent (designated d 0), cells were
switched to high insulin (1.7 M), high glucose DMEM supple-
mented10%fetal bovine serum(FBS).Differentiationof3T3-L1
preadipocytes was induced at d 2 by switching to high insulin,
high glucose DMEM supplemented with 10% FBS, 1 M dexa-
methasone, and0.5mM3-isobutyl-l-methylxanthine.After 48h,
the medium was switched back to high insulin, high glucose
DMEMsupplemented 10%FBS.Differentiated adipocyteswere
exposed to one of three doses of acyl-ghrelin (AG) or desacyl-
ghrelin (DAG) (Bachem;Torrance,CA) calculated to correspond
with the concentrations seen in the VSG-operated animals (AG
low, 22 pmol/liter; and DAG low, 89 pmol/liter) and the S-WM
animals (AG medium, 65 pmol/liter; and DAG medium, 260
pmol/liter).Ahighdose (AGhigh,130pmol/liter; andDAGhigh,
520 pmol/liter) corresponding to a 2-fold higher dose than the
medium dose was also included. The concentration of AG pres-
ent in the circulationwas estimatedusing the 1-month total ghre-
lin concentration data set and previously published data dem-
onstrating a 1:5 ratio of acyl to total ghrelin in the circulation in
rats (28).Cellswere incubatedwith the appropriate dose of ghre-
lin for 24 h, and then media were collected for assessment of
adiponectin secretion by RIA, and mRNA was extracted from
cells using TRIzol reagent (Invitrogen, Carlsbad, CA) for assess-
ment of adiponectin mRNA expression. cDNA was generated
using high-capacity cDNA RT kit (Applied Biosystems, Foster
City, CA). Adiponectin mRNA levels were determined by real-
time PCR (iCycler; Bio-Rad, Hercules, CA) and normalized to
TATA box-binding protein (TBP). Primers used were adiponec-
tin forward, GTTGCAAGCTCTCCTGTTCC and adiponectin
reverse, CTCCAGGAGTGCCATCTCT; TBP forward, GAAG
CTGCGGTACAATTCCAG and TBP reverse, CCCCTTGTA
CCCTTCACCAAT.
Statistics and data analysis
Data are presented as mean  SEM. Statistical analyses were
performed using GraphPad Prism 4.00 forWindows (GraphPad
Software, San Diego, CA). The incidence of diabetes was ana-
lyzed by log-rank testing of Kaplan-Meier survival curves. All
other data were analyzed by two-factor (time  treatment) re-
peated measures ANOVA followed by post hoc analysis with
Bonferroni’s multiple comparison test or Student’s t test as in-
dicated. Differences were considered significant at P  0.05.
Values are expressed as mean  SEM.
Results
VSG surgery delays the onset of diabetes
ComparedwithS-ALanimals, theonset of diabeteswas
delayed in S-WM and VSG-operated animals by approx-
imately 1 and 3.5 months, respectively. Furthermore, the
age of diabetes onset was delayed in VSG-operated ani-
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mals comparedwith S-WManimals by approximately 2.5
months. The mean ages of diabetes onset were 6.1 0.5,
7.0  0.2, and 9.6  0.2 months in S-AL, S-WM, and
VSG-operated animals, respectively (P 0.05 VSG com-
paredwithS-WMandS-AL) (Table1).By8monthsof age,
none of the VSG-operated animals had become diabetic,
whereas 3/16 S-WM and 11/14 S-AL animals were dia-
betic. Thus, within the first 8 months of age, VSG signif-
icantly delayed diabetes onset compared with both the
S-AL and S-WM groups (P  0.05) (Fig. 1A). At 1 yr of
age, S-WMandVSG-operated animals both exhibited sig-
nificantly delayed diabetes onset compared with S-AL an-
imals (P 0.001), but at this small sample size and longer
time course, the time of onset was not significantly differ-
ent between S-WM and VSG groups by Kaplan-Meier
analysis. Similarly, diabetes-free days up to 1 yr of age
were significantly greater in S-WMandVSG-operated an-
imals comparedwithS-ALanimals (P0.001)butdidnot
differ between S-WM and VSG-operated animals (Table
1). The delay in the onset of diabetes corresponded with
lower fasting serum glucose concentrations in S-WM
and VSG-operated animals compared with S-AL ani-
mals (Fig. 1B).
As expected, energy intake and body weight were
higher in S-AL animals compared with S-WM and VSG-
operated animals (P  0.001) (Fig. 2, A and B). Energy
intake was reduced by approximately 23% in VSG-oper-
ated animals compared with S-AL. Energy intake and
body weight did not differ between S-WM and VSG-op-
erated animals. Energy expenditure in VSG-operated an-
imals did not differ compared with S-AL or S-WMgroups
(Fig. 2, C and D). However, energy expenditure was ap-
proximately 5% lower in S-WM animals compared with
S-AL (P 0.05). The observed decrease of energy expen-
diture with restriction of energy intake is similar to that
reported in previous rodent and primate studies examin-
ing the effect of chronic energy intake restrictionon energy
expenditure (29, 30). It is interesting that surgically in-
duced energy restriction did not produce a similar effect
and suggests a mechanism by which bariatric surgery pa-
tients are better able to defend bodyweight loss after bari-
atric surgery compared with dieting alone (31).
VSG surgery improves circulating lipids and
hormones
Monthly fasting plasma insulin remained significantly
lower inVSG-operated animals comparedwith both S-AL
and S-WM animals up to 3 months after surgery (P 
0.001), at which point, insulin values began to decline in
S-AL animals due to the onset of diabetes and progressive
-cell decompensation (Fig. 3A). Circulating insulin con-
centrations continued to be lower in VSG-operated ani-
mals compared with S-WM up to 5 months after surgery,
suggesting an improvement of insulin sensitivity, indepen-
dent of body weight (P  0.01). Fasting plasma leptin
concentrations remained lower in VSG-operated animals
compared with S-WM up to 5 months after surgery (P 
0.01) (Fig. 3B). We have previously reported that fasting
plasma leptin concentrations increase in the UCD-T2DM
rat before diabetes onset due to increasing adiposity and
increasing circulating insulin concentrations. Conversely,
fasting plasma leptin concentrations decrease after diabe-
tes onset in the UCD-T2DM rat due to decreasing adipose
mass and decreasing circulating insulin concentrations
(21). Leptin concentrations in S-AL animals began to de-
cline at 3 months after surgery, likely due to the increased
prevalence of diabetes and corresponding decreases of cir-
culating insulin concentrations and adipose mass.
Circulating lipids weremarkedly improved in VSG-op-
erated animals compared with both S-AL and S-WM an-
imals. Fasting plasmaTGconcentrationswere 50% lower
inVSG-operated animals comparedwith S-AL and S-WM
up to 5 months after surgery (P  0.001) (Fig. 3C). Fur-
thermore, fasting plasma cholesterol concentrations were
lower in VSG-operated animals compared with S-AL and
S-WMup to 5months after surgery (P 0.001) (Fig. 3D).
Similar toprevious studies in both rodents andhumans,
fasting plasma ghrelin concentrationswere reduced by ap-
proximately 75% in VSG-operated animals compared
with both S-AL and S-WM (P 0.001) (Fig. 3E). Fasting
plasma adiponectin concentrations were elevated in
S-WM and VSG-operated animals compared with S-AL
(P 0.001) (Fig. 3F). However, fasting plasma adiponec-
tin concentrations were further elevated in VSG-operated
animals compared with S-WM, demonstrating a weight-
independent increase of circulating adiponectin concen-
trations after VSG surgery (P  0.05) (Fig. 3F).
A previous study reported that incubation of brown
adipocytes with ghrelin impairs adiponectin production
(32). Thus, we hypothesized that decreases of circulating
ghrelin in VSG-operated animals may have contributed to
the bodyweight-independent augmentation of circulating
TABLE 1. Age of diabetes onset and incidence in
animals followed to 1 yr of age
S-AL S-WM VSG
Age of onset (d) 182  16 210  6 288  23a
Incidence (%) 100 19 23
Diabetes-free days 182  16 336  16b 347  9b
n 14 16 13
Values are mean  SEM.
a P  0.05 compared with S-AL and S-WM.
b P  0.001 compared with S-AL by Student’s t test.
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adiponectin concentrations. To test this hypothesis, we
exposed differentiated 3T3-L1 adipocytes to concentra-
tions of acylated ghrelin calculated from the total ghrelin
concentrations (28) measured in the VSG-operated ani-
mals (AG low) and from the ghrelin concentrations mea-
sured in the S-WM animals (AG medium) and a dose
2-fold higher than the medium dose of ghrelin (AG high).
Adiponectin secretion and mRNA expression were not
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affected by exposure to AG concentrations similar to the
concentrations found in VSG-operated animals. How-
ever, adiponectin secretion and mRNA expression were
reduced in a step-wise manner with exposure to AG con-
centrations similar to the concentrations found in S-WM
animals as well as by 2-fold higher AG concentrations.
Incubation of differentiated 3T3-L1 adipocytes with similar
concentrations of inactive DAG did not affect adiponectin
secretion or adiponectin mRNA expression (Fig. 4).
VSG surgery increases circulating bile acid
concentrations
Circulating bile acid profiles did not differ between
groups at baseline (Fig. 5A). At 3 months after surgery,
there was a 2-fold increase of circulating deoxycholic acid
concentrations (P  0.05), but total circulating bile acid
concentrations did not differ between groups (Fig. 5B).
However, at 5 months after surgery, total bile acid con-
centrations and all bile acid subtype concentrations were
elevated in VSG-operated animals compared with S-AL
and S-WM (P  0.05) (Fig. 5C). The elevation of circu-
lating total bile acid concentrations in VSG-operated an-
imals was primarily due to an increase of conjugated bile
acids as both an absolute value and as a percentage of the
total bile acid pool (P  0.05) (Fig. 6, A and B). Specifi-
cally, taurine-conjugated bile acids were elevated approx-
imately 3-fold in VSG-operated animals compared with
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with S-AL and S-WM by two-factor repeated measures ANOVA. ***, P  0.001; **, P  0.01; *, P  0.05 compared with S-AL; ###, P  0.001
##, P  0.01; #, P  0.05 compared with S-WM by Bonferroni’s post hoc test.
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S-AL and S-WM (P  0.05) (Fig. 6, A and B). Glycine-
conjugated bile acids did not differ between groups as an
absolute value (Fig. 6C), but glycine-conjugated bile acids
as a proportion of total conjugated bile acids were lower
inVSG-operated animals comparedwith S-AL and S-WM
(P  0.05) (Fig. 6D). Fasting plasma-unconjugated bile
acids did not differ between groups when expressed as an
absolute value (Fig. 6E). However, unconjugated bile ac-
ids were proportionally lower in VSG-operated animals
compared with S-AL and S-WM (P  0.05) (Fig. 6F).
Thus, VSG surgery results in a preferential increase of
circulating taurine-conjugated bile acid concentrations.
VSG surgery improves insulin secretion and
increases nutrient-stimulated GLP-1, GLP-2, and
PYY secretion
OGTTwere performed at 1 and 4months after surgery
to assess changes of glucose tolerance and nutrient-stim-
ulated gastrointestinal hormone secretion over time. Glu-
cose excursions were significantly lower in S-WM and
VSG-operated animals at both 1 and 4 months after sur-
gery (P  0.01) (Fig. 7, A and B). VSG resulted in signif-
icantly lower insulin excursions, as indexed by area under
the curve (AUC), compared with S-WM at both 1 and 4
months after surgery, suggesting an improvement of in-
sulin sensitivity (P 0.05) (Fig. 7, C and D). At 4 months
after surgery, insulin excursionsweremarkedly blunted in
S-AL animals due to the greater prevalence of diabetes in
this group and the concomitant impairment of-cell func-
tion (Fig. 7D). Importantly, the percent increase of plasma
insulin concentrations from fasting to peak values was
significantly higher in VSG-operated animals compared
with both S-AL and S-WMduring both the 1 and 4month
OGTT, demonstrating superior islet function in VSG-op-
erated animals (P  0.01) (Fig. 7, C and D).
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Peak plasma GLP-1 concentrations were 3-fold
higher in VSG-operated animals compared with S-AL
and S-WManimals at both 1 and 4months after surgery
(P  0.001) (Fig. 7, E and F). Furthermore, GLP-1 ex-
cursions were significantly higher at 4 months after
surgery comparedwith at 1month after surgery in VSG-
operated animals, demonstrating preservation of post-
operative increases of postprandial GLP-1 secretion
(P  0.05). The GLP-1 AUC was significantly lower in
S-WM compared with S-AL animals during both the 1
and 4 month OGTT (P  0.05). Similarly, nutrient-
stimulatedGLP-2 secretionwas significantly elevated in
VSG-operated animals compared with S-AL and S-WM
(P  0.05) (Fig. 7, G and H). This effect was preserved
up to 4 months after surgery.
PYY excursions were markedly elevated in VSG-oper-
ated animals compared with S-AL and S-WM animals at
both1and4months after surgery (P0.001) (Fig. 7, I and
J). Although the PYY AUC in VSG-operated animals
tended to be higher at 4 months after surgery compared
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with 1 month after surgery, this difference did not reach
statistical significance. However, these data also demon-
strate the durability of postoperative increases of post-
prandial PYY secretion in VSG-operated animals.
Discussion
In this study, we demonstrate that VSG performed in pre-
diabetic male UCD-T2DM rats delays the onset of type 2
diabetes and results in long-lasting improvements of glu-
cose and lipid metabolism. Postoperative decreases of
food intake and body weight contributed to the delay in
diabetes onset, as there was approximately a 5-month in-
crease in thenumberof diabetes-freemonths in S-WMand
VSG-operated animals compared with S-AL. However,
metabolic and endocrine changes after VSG surgery likely
contributed to the delay in diabetes onset, as VSG surgery
resulted in a significantly higher age of diabetes onset and
a significant delay in diabetes onset up to 8 months of age
byKaplan-Meier analysis comparedwithweight-matched
controls. The weight-independent metabolic and endo-
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crine changes that we observed after VSG surgery that
likely contributed to the delay in diabetes onset include
increased postprandial GLP-1 secretion, increased circu-
lating bile acid and adiponectin concentrations, and de-
creased circulating ghrelin concentrations.
Glucose-stimulated GLP-1 and GLP-2 secretion were
elevated at both 1 and 4 months after surgery in VSG-
operated animals. Postprandial GLP-1 secretion in VSG-
operated animals was further elevated at 4 months after
surgery compared with 1 month after surgery, demon-
strating that this response does not taper over time. The
“hind-gut” hypothesis postulates that increases of post-
prandial GLP-1 secretion after bariatric surgery are due to
increased delivery of incompletely absorbed nutrients to
the distal small intestine, resulting in direct stimulation of
L cells to release GLP-1 (33). Although VSG surgery in-
creases gastric emptying (34), the ability ofVSG surgery to
increase the flux of incompletely absorbed nutrients in the
distal small intestine is questionable, because it does not
involve bypass of the proximal small intestine. Further-
more, human clinical studies have demonstrated similar
postprandial GLP-1 secretion profiles after VSG com-
pared with RYGB (9). This suggests that mechanisms
other than that proposed in the hind-gut hypothesis may
contribute to postoperative increases of postprandial
GLP-1 secretion. One potential contributor is activation
of a vagal reflex by nutrients in the proximal small intes-
tine (19).
Increases of GLP-1 secretion likely contributed to the
improvement of insulin sensitivity and islet function. Im-
provement of glucose-stimulated insulin secretionwas ob-
served during the OGTT at 1 and 4 months after surgery,
in which VSG-operated animals exhibited approximately
2-fold greater glucose-stimulated insulin secretion com-
pared with both S-AL and S-WM animals. As an incretin
hormone, GLP-1 potentiates glucose-stimulated insulin
secretion (18). Furthermore, GLP-1 has been shown to
have beneficial effects on the islet by increasing insulin
synthesis, stimulating -cell proliferation, and preventing
-cell apoptosis (35). Increases of GLP-2 secretion may
have contributed to the increases of nutrient-stimulated
GLP-1 secretion, because GLP-2 is known to stimulate
proliferation of intestinal cells and thus may contribute to
an increase in L-cell number (36). Nutrient-stimulated
GLP-2 secretion has been shown to be elevated after ileal
interposition (IT) surgery in rats and early afterRYGBand
VSG in humans (37, 38). However, this study demon-
strates that the increased GLP-2 response is maintained
over time.
The decreases of fasting circulating insulin concentra-
tions and decreased insulin AUC during both the 1 and 4
month OGTT compared with weight-matched animals
suggest an improvement of insulin sensitivity that is inde-
pendent of body weight. Increases of nutrient-stimulated
GLP-1 secretion may have improved insulin sensitivity by
reducing glucotoxicity and lipotoxicity. GLP-1 reduces
glucotoxicity by improving islet function and reducing he-
patic gluconeogenesis (18). GLP-1 may contribute to re-
ductions in lipotoxicity by stimulating fat oxidation (39).
VSG-operated animals exhibited improvements of lipid
metabolism with markedly lower fasting plasma lipids.
Bile acids have been shown to be elevated after RYGB
and IT surgery and may represent another mechanism in-
volved in the metabolic improvements after bariatric sur-
gery (40, 41). Here, we found marked increases of total
circulating bile acid concentrations at 5 months after sur-
gery. These increases were similar in magnitude to those
reported in obese rats after IT surgery. However, bile acid
profiles were different in VSG-operated animals com-
pared with what has been previously reported after IT
surgery (40). The increase of circulating bile acid concen-
trations after VSG surgery was primarily due to increased
taurine-conjugated bile acids with proportional decreases
of unconjugated bile acid concentrations. In contrast,
Kohli et al. (40) report marked preferential increases of
unconjugated bile acids along with increases of glycine
and taurine-conjugated bile acid concentrations. These
differences in circulating bile acid profiles between IT and
VSG surgery suggest that the mechanisms responsible for
postoperative increases of circulating bile acid concentra-
tions likely differ based on the type of bariatric surgery
performed.
The increases of circulating bile acid concentrations
after VSG surgery may have contributed to the observed
improvements of insulin sensitivity and circulating lipids.
Bile acids have been shown to decrease hepatic gluconeo-
genesis and lipogenesis and increase insulin-mediated glu-
cose disposal in adipocytes by signaling through farnesoid
X receptor (42). Furthermore, administration of taurine-
conjugated bile acids to rats has been shown to improve
insulin signaling and decrease the expression of gluconeo-
genic genes, likely by signaling through farnesoid X re-
ceptor (43). Bile acids have also been shown to signal
through TGR5 receptors located in the distal small intes-
tine to increase GLP-1 secretion and through TGR5 re-
ceptors on skeletal muscle and brown adipose tissue to
increase energy expenditure (42, 44). Energy expenditure
did not differ between VSG-operated animals and con-
trols. However, energy expenditure was measured at 1.5
months after surgery, before a significant increase of cir-
culating bile acid concentrations was observed.
Similar to previous studies of RYGB and VSG, circu-
lating adiponectin concentrations were significantly ele-
vated after VSG surgery compared with ad libitum-fed
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controls (45). However, to our knowledge, this is the first
study to demonstrate postoperative increases of circulat-
ing adiponectin concentrations compared with a weight-
matched control, indicating that postoperative increases
of circulating adiponectin are likely due to additional
mechanisms beyond the reduction of body weight. We
hypothesized that decreases of circulating ghrelin concen-
trations afterVSGsurgery contributed to thebodyweight-
independent effects of VSG surgery to increase circulating
adiponectin concentrations. This is supported by our in
vitro results demonstrating significant inhibition of both
adiponectin mRNA expression and secretion in 3T3-L1
adipocytes exposed to active acylated ghrelin concentra-
tions similar to those of sham-operated animals. Increases
of circulating adiponectin likely contributed to the im-
provementof insulin sensitivity andcirculating lipids.Adi-
ponectin is an adipokine that has been demonstrated to
improve insulin sensitivity and lipidmetabolism (46). Fur-
thermore, circulating adiponectin concentrations are re-
duced in obesity and type 2 diabetes (47). Adiponectin has
been proposed to improve insulin sensitivity by signaling
in liver and skeletal muscle through activation of AMP
kinase to promote decreased gluconeogenesis, in-
creased insulin-mediated glucose uptake, and increased
fatty acid oxidation resulting in decreased ectopic lipid
deposition (46).
Similar to previous studies in rodents and humans, we
demonstrated a marked decrease of circulating ghrelin
concentrations after VSG surgery (10, 48). Decreased cir-
culating ghrelin concentrations likely contributed to re-
duced food intake, improved glucose-stimulated insulin
secretion, and improved insulin sensitivity. Ghrelin has
been shown topromote food intake and increase adiposity
(49). Reductions of circulating ghrelin likely contributed
to improved islet function, because previous studies have
demonstrated that both physiologic and pharmacologic
doses of exogenous ghrelin impair glucose-stimulated in-
sulin secretion in cell culture studies and in humans (15,
17). This has been suggested to be mediated by activation
of voltage-dependent K channels resulting in decreased
calcium-mediated insulin release (15). Ghrelin has also
been shown to promote insulin resistance, because abla-
tion of ghrelin in both the ob/ob mouse and high-fat-fed
mice has been shown to improve insulin sensitivity (16).
Furthermore, inhibition of ghrelin activation by ghrelin
o-acyltransferase using a ghrelin o-acyltransferase antag-
onist results in improvement of glucose tolerance and
bodyweight,making ghrelin an attractive pharmaceutical
target for the treatment of type 2 diabetes (50).
In conclusion, we have shown for the first time that
VSG surgery delays diabetes onset in the UCD-T2DM rat
model of type 2 diabetes, an effect that is partially inde-
pendent of reduced body weight. Furthermore, VSG sur-
gery results in marked improvements of glucose and lipid
metabolism with improved islet function and decreased
circulating lipids. Increases of circulating adiponectin, bile
acids, and GLP-1 concentrations and decreases of circu-
lating ghrelin all likely contributed to the effect of VSG
surgery to delay type 2 diabetes onset. Further studies on
the effect of VSG surgery and other bariatric surgeries to
delay type2diabetes onset in theUCD-T2DMratwill help
to identify new pharmaceutical targets for the treatment
and prevention of type 2 diabetes.
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